Here at Ximbio we have seen a rapid expansion in the number of US institutes partnering with us over the past six months. Each of these institutions is at a different stage of their Ximbio partnership, with each stage of the partnership providing unique benefits and opportunities:
Identifying any lost or forgotten reagents - Rutgers University has recently established a Ximbassador program on campus. The role of the Ximbassador is to work with Ximbio, to benefit their institution by finding any lost or forgotten reagents that could be of scientific or commercial interest.
Commercialising reagents - Ximbio commercialises any reagents that are identified as being of commercial or scientific interest. As part of the partnership process, reagents are identified and added to the Ximbio portfolio. Some of the newest reagents added to the portfolio from the University of Iowa, Versiti Blood Research Institute and Johns Hopkins include:
- SOD2 Cell line - The first known human cell line that completely lacks superoxide dismutase 2. Providing an invaluable model of mitochondrial function.
- Anti-Integrin Beta 3a (GPIIIa, CD61) - Glycoprotein IIb/IIIa, also known as integrin aIIbß3 is an integrin complex found on platelets with a role in platelet activation
- Anti-SUMO-2/SUMO-3 (8A2) monoclonal antibody - Small ubiquitin-like modifiers (SUMO) post-translationally modify proteins through SUMOylation. SUMOylation of lysine residue is significant in nuclear transport, DNA replication and repair, transcription, protein stability, mitochondrial fission, signal transduction, mitosis and apoptosis.
To view all the latest reagents sourced from US institutes, visit our portfolio.
Depositing Reagents – Any reagents that have been identified either by the Ximbassadors or the Technology Transfer Office (TTO) are then stored in either our own repository or one of the many repositories we have agreements with. This helps the institute to save time as it can take advantage of our existing repository agreements. We are currently working with the Versiti Blood Research Institute to deposit over 40 of its hybridomas within our own repository.
Find out more about the repositories Ximbio has agreements with.
Due diligence and licensing – We work with institutes to safeguard their reagents, by conducting due diligence to ensure ownership and licencing requirements are fully covered and to prevent the loss of income or ownership rights for an institute. We will then work to make these reagents available to the research community through Material Transfer Agreements with other academic groups or through commercial licences with life science suppliers and researchers.
Portfolio management – We manage a worldwide portfolio of research reagents, ensuring all reagents are well maintained and easy to access. Every Ximbio customer is assigned a Portfolio manager who manages and responds to questions on our portfolio, liaises with your TTO through its portfolio managers to ensure all reagent profiles are up-to-date and generates revenue for your institute at no extra cost to you.
Our flexible approach to partnering with research institutes helps to ensure success in meeting the goals of researchers, TTO’s and commercial partners alike. It increases the revenue opportunities for each reagent by focusing on their screening, commercialisation and management to achieve the full scientific and commercial potential available.